BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22956062)

  • 1. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000.
    Solá M; Alberro JA; Fraile M; Santesteban P; Ramos M; Fabregas R; Moral A; Ballester B; Vidal S
    Ann Surg Oncol; 2013 Jan; 20(1):120-7. PubMed ID: 22956062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of sentinel lymph node micrometastasis in breast cancer: Comparing outcomes with and without axillary clearance.
    Youssef MMG; Cameron D; Pucher PH; Olsen S; Ferguson D
    Breast; 2016 Dec; 30():101-104. PubMed ID: 27668857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence.
    Pernas S; Gil M; Benítez A; Bajen MT; Climent F; Pla MJ; Benito E; Guma A; Gutierrez C; Pisa A; Urruticoechea A; Pérez J; Gil Gil M
    Ann Surg Oncol; 2010 Mar; 17(3):772-7. PubMed ID: 20183912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes.
    Houvenaeghel G; Boher JM; Reyal F; Cohen M; Garbay JR; Classe JM; Rouzier R; Giard S; Faure C; Charitansky H; Tunon de Lara C; Daraï E; Hudry D; Azuar P; Gimbergues P; Villet R; Sfumato P; Lambaudie E
    Eur J Cancer; 2016 Nov; 67():106-118. PubMed ID: 27640137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up.
    Avril A; Le Bouëdec G; Lorimier G; Classe JM; Tunon-de-Lara C; Giard S; MacGrogan G; Debled M; Mathoulin-Pélissier S; Mauriac L;
    Eur J Surg Oncol; 2011 Jul; 37(7):563-70. PubMed ID: 21665421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma.
    Cipolla C; Graceffa G; La Mendola R; Fricano S; Fricano M; Vieni S
    Ann Ital Chir; 2015; 86():497-502. PubMed ID: 26898168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series.
    Grossmith S; Nguyen A; Hu J; Plichta JK; Nakhlis F; Cutone L; Dominici L; Golshan M; Duggan M; Carter K; Rhei E; Barbie T; Calvillo K; Nimbkar S; Bellon J; Wong J; Punglia R; Barry W; King TA
    Ann Surg Oncol; 2018 Nov; 25(12):3527-3534. PubMed ID: 29868979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevalence of micrometastases and isolated tumor cells in the sentinel node at early stage breast cancer].
    Cordero García JM; Palomar Muñoz A; Delgado Portela M; García Vicente AM; Pilkington Woll JP; Poblete García VM; Bellón Guardia ME; Pardo García R; Rabadán Ruiz L; Soriano Castrejón A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):78-82. PubMed ID: 21658817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive versus negative sentinel nodes in early breast cancer patients: axillary or loco-regional relapse and survival. A study spanning 2000-2012.
    García Fernández A; Chabrera C; García Font M; Fraile M; Lain JM; Barco I; González C; Gónzalez S; Reñe A; Veloso E; Cassadó J; Pessarrodona A; Giménez N
    Breast; 2013 Oct; 22(5):902-7. PubMed ID: 23684000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of axillary lymph node dissection (ALND) in patients with micrometastatic breast cancer.
    Collins M; O'Donoghue C; Sun W; Zhou JM; Ma Z; Laronga C; Lee MC
    J Surg Res; 2017 Jul; 215():55-59. PubMed ID: 28688661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of axillary recurrence in 344 sentinel node negative breast cancer patients after intermediate follow-up. A prospective study into the accuracy of sentinel node biopsy in breast cancer patients.
    Heuts EM; van der Ent FW; Hulsewé KW; Heeren PA; Hoofwijk AG
    Acta Chir Belg; 2007 Jun; 107(3):279-83. PubMed ID: 17685253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
    Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
    Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy.
    Langer I; Marti WR; Guller U; Moch H; Harder F; Oertli D; Zuber M
    Ann Surg; 2005 Jan; 241(1):152-8. PubMed ID: 15622003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Incidence of axillary recurrence after a negative sentinel lymph node result in early stages of breast cancer: a 5-year follow-up].
    Ruano Pérez R; Ramos Boyero M; García-Talavera Fernández JR; Ramos Grande T; González-Orús JM; Gómez-Caminero López F; García Macias MC; Martín de Arriba A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(4):173-7. PubMed ID: 23067685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omission of axillary lymph node dissection for clinically node negative early-stage breast cancer patients.
    Kobayashi R; Shiraishi K; Iwase S; Ohtomo K; Nakagawa K
    Breast Cancer; 2015 Nov; 22(6):657-63. PubMed ID: 24756246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection.
    Erbes T; Orlowska-Volk M; Zur Hausen A; Rücker G; Mayer S; Voigt M; Farthmann J; Iborra S; Hirschfeld M; Meyer PT; Gitsch G; Stickeler E
    BMC Cancer; 2014 Jan; 14():4. PubMed ID: 24386929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.